Clinical trials: Gout Flare
Acute Gouty Arthritis
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.
- Trial name
- NCT01356602
- Testing
- Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide
- Where
- 99 sites in United States, Canada and 3 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gout
Clinical Study of Genakumab for Injection in Patients With Acute Gout
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout
- Trial name
- NCT05328531
- Testing
- Genakumab for Injection
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Acute Gouty Arthritis Flares
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any…
- Trial name
- β-RELIEVED (NCT01470989)
- Testing
- ACZ885, Triamcinolone acetonide 40 mg
- Where
- 56 sites in United States, Australia and 7 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gout, Gout Flare
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy
- Trial name
- Gensci 048-203 (NCT05936268)
- Testing
- Genakumab for injection, Colchicine
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Gout
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
A Phase IIA, open-label, multicenter, active-controlled, parallel-group clinical trial designed to evaluate the safety and efficacy of two doses of Bucillamine compared with low-dose Colchicine in the treatment of patients with…
- Trial name
- NCT02330796
- Testing
- Bucillamine, Colchicine
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Revive Therapeutics, Ltd.
Acute Gout
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)
A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.
- Trial name
- NCT00142558
- Testing
- MK0663; etoricoxib / Duration of Treatment: 5 Days, Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Acute Gouty Arthritis, Acute Pain
Treatment of Topical Ketorolac Gel in Acute Gouty Flare
This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac…
- Conditions
- Acute Gouty Arthritis, Acute Pain, Gout Flare
- Trial name
- NCT06273813
- Testing
- Ketorolac Tromethamine 15 MG/ML, Ketorolac Tromethamine
- Where
- 2 sites in Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novilla Pharmaceuticals
Acute Gout Flare
Study Utilizing Rilonacept in Gout Exacerbations
This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days.
- Trial name
- SURGE (NCT00855920)
- Testing
- Rilonacept, Indomethacin
- Where
- 44 sites in United States
- Volunteers
- 225 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gout
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine.
- Trial name
- NCT00798369
- Testing
- Canakinumab, Triamcinolone acetonide
- Where
- 75 sites in United States, Argentina and 9 more
- Volunteers
- 200 people
- Sponsor
- Novartis
Acute Gout Arthritis
Safety & Efffficacy of Genakumab in Patients With Frequent Flares
The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).
- Trial name
- NCT05983445
- Testing
- genakumab, Diprospan
- Where
- China
- Volunteers
- 313 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Gout Flares
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis.
- Trial name
- NCT01712204
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- TWi Biotechnology, Inc.
Gout
Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
This overall goal of this trial will be to demonstrate that DYV700 is safe and effective as a treatment for acute gout flares.
- Trial name
- TARGETS (NCT04130204)
- Testing
- DYV700, Colchicine 0.6 mg
- Where
- United States
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Dyve Biosciences, Inc.
Gouty Arthritis
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all…
- Trial name
- NCT00927810
- Testing
- Canakinumab
- Where
- 45 sites in United States, Argentina and 16 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gouty Arthritis
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis
The purpose of this study is to evaluate how anakinra relieves pain for patients with acute gout that cannot take non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine.
- Trial name
- anaGO (NCT03002974)
- Testing
- Anakinra 100 mg, Triamcinolone Acetonide 40 mg
- Where
- 37 sites in United States
- Volunteers
- 165 people
- Sponsor
- Swedish Orphan Biovitrum
Acute Gouty Arthritis
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.
- Trial name
- NCT01431638
- Testing
- Canakinumab 150mg in prefilled syringe
- Where
- 68 sites in United States, Canada and 2 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Gout
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating…
- Trial name
- NCT00819585
- Testing
- Canakinumab, Colchicine, Allopurinol
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Gout Arthritis
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
- Trial name
- NCT07708181
- Testing
- SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W
- Volunteers
- 200 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gouty Arthritis
A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis
This study will evaluate the efficacy and safety of Qingzhu Granules in the treatment of Acute Gouty Arthritis ( Damp heat pattern)
- Trial name
- NCT06068478
- Testing
- Qingzhu Granules
- Where
- 29 sites in China
- Volunteers
- 472 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Acute Gout
A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
The purpose of this study is to determine the efficacy and safety of recombinant anti-IL-1β humanized monoclonal antibody injection in Chinese participants with acute gout.
- Trial name
- NCT06169891
- Testing
- Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg, Compound Betamethasone Injection
- Volunteers
- 500 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.